Quick Takeaways
- JANUS HENDERSON GROUP PLC filed SCHEDULE 13G for ENANTA PHARMACEUTICALS INC Common Stock (ENTA).
- Disclosed ownership: 12%.
- Date of event: 31 Oct 2025.
JANUS HENDERSON GROUP PLC - 31 Oct 2025 SCHEDULE 13G Report for ENANTA PHARMACEUTICALS INC Common Stock (ENTA)
- Filing Manager
- JANUS HENDERSON GROUP PLC
- Reporting Manager
- JANUS HENDERSON GROUP PLC
- Symbol
- ENTA
- Shares outstanding
- 28,876,595 shares
- Disclosed Ownership
- 3,494,068 shares
- Ownership
- 12%
- Form type
- SCHEDULE 13G
- Filing time
- 07 Nov 2025, 12:10:28 UTC
- Date of event
- 31 Oct 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"JANUS HENDERSON GROUP PLC disclosed 12% ownership in ENANTA PHARMACEUTICALS INC Common Stock (ENTA) on 31 Oct 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 07 Nov 2025, 12:10.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 12% | 3,494,068 | 0 | 3,494,068 | Kristin Mariani | Head of North America Compliance, CCO | |
| Janus Henderson Biotech Innovation Master Fund Ltd | 11% | 2,959,525 | 0 | 2,959,525 | Kristin Mariani | Head of North America Compliance, CCO |